No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Executive Reshuffles: CAT, LMT, and APA
SA Asks: What's the Best Weight-loss Drug Stock Right Now?
ANGPTL3 Inhibitor Market Set for Robust Growth During the Forecast Period (2025-2034) Across 7MM Owing to the Rising Demand for Novel Lipid-Lowering Therapies | DelveInsight
Don't Ignore The Insider Selling In Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals' Ken Myszkowski To Retire As CFO; Daniel Apel Appointed As New CFO
Express News | Arrowhead Pharmaceuticals Inc - Ken Myszkowski to Retire as CFO of Arrowhead Pharmaceuticals - SEC Filing